Moxclav is a combination medicine containing the semisynthetic antibiotic Amoxycillin and the βlactamase inhibitor, Potassium clavulanate (βlactamase is a type of enzyme produced by bacteria that resists Amoxycillin action).
Amoxycillin has a bactericidal effect. However, it is susceptible to hydrolysis by
Β- lactamases. Addition of clavulanic acid extends the antimicrobial spectrum and activity of amoxycillin.
β-lactamase resistance is an increasing problem that results in treatment failure in many common infections. Moxclav first overcomes the β-lactamase resistance,
then deals with the bacteria.
Moxclav is indicated in various bacterial infections like, Skin and Skin Structure Infections,
Moxclav is brand from Sun Pharmaceuticals. Established in 1983, Sun Pharmaceuticals has more than 40 manufacturing units with world-class quality in design, equipment and operations in all manufacturing facilities across 6 continents.
Moxclav is an orally available combination antibiotic drug. The medicine contains two combinations. Amoxicillin is a penicillin type antibiotic which works by preventing bacteria from growing, and killing them. Clavulanic Acid when combined with penicillin-group antibiotics can overcome antibiotic resistance in bacteria, which otherwise inactivates most penicillins.
Bacterial Infections are caused by infectious bacteria which reproduce quickly in the body and may even give out toxins which can damage tissues and make you very ill.
Bacterial Infections differ from other infections due to the microbes that cause them. Even though less than one percent of bacteria can make humans sick, bacterial infections can range from minor illnesses such as sore throat and ear infections to more life-threatening conditions like meningitis and encephalitis.
Patients infected by bacteria have to be treated with antibiotics. Moxclav can be used to treat bacterial infections that may include:
Middle ear infection
Urinary tract infection
Moxclav has been known to work well among patients with various bacterial infection.
Patient w/ mononucleosis. Renal and hepatic impairment. Children. Pregnancy and lactation.
Monitoring Parameters- Periodically monitor renal, hepatic and haematologic function.
Monitor for signs of anaphylaxis during 1st dose.
Hypersensitivity to penicillins. History of severe immediate hypersensitivity reaction to another β-lactam agent (e.g. cephalosporins, carbapenem or monobactam), history of cholestatic jaundice/hepatic dysfunction associated w/ amoxicillin and clavulanic acid therapy.
May increase plasma concentration of amoxicillin w/ probenecid. May increase allergic or hypersensitivity reaction w/ concomitant use of allopurinol and amoxicillin. May reduce efficacy of oral oestrogen/progesterone contraceptives.
Symptoms: GI symptoms, fluid and electrolyte imbalances; crystalluria and interstitial nephritis may lead to renal failure.
Management: Treat symptomatically w/ attention to water/electrolyte balance. May be removed by haemodialysis.
Mechanism of Action
Clavulanic acid has a high affinity for and binds to certain β-lactamases that generally inactivate amoxicillin by hydrolysing its β-lactam ring. Combining clavulanate K w/ amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.